If this email is not displayed correctly please click here

Healthcare & Life Sciences

01 April 2020
Chen Li OCT benefits cap and private label product restrictions abolished

Canada - Smart & Biggar

Most of the final amendments to regulations made under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act came into effect on or before 1 January 2020, following public consultations. One notable change compared with the proposed amendments is the removal of the financial cap on ordinary commercial term benefits. Further, private label products will no longer be prohibited from being designated as a listed drug product or interchangeable.

Authors: Chen Li, Alice Tseng
Read more
Adam Bell COVID-19 Weekly Report (23-30 March 2020)

International - International Law Office

The impact of COVID-19 is being felt in almost every work area across the globe. In order to keep readers abreast of this evolving situation, ILO's COVID-19 Weekly Report provides insight into the major legal developments of the past seven days, as well as a round-up of our panel of expert international legal commentators' legislative and regulatory guidance.

Author: Adam Bell
Read more
Andreas Wildi CAR-T therapies and changes to Healthcare Benefits Ordinance

Switzerland - Walder Wyss

The Federal Department of Home Affairs recently decided that two new autologous cell therapies (CAR-T therapies) for the treatment of blood and lymph gland cancer will in future be covered by compulsory healthcare insurance. Further, preventive investigations of colorectal cancer will be exempted from the franchise in the Cantons of Fribourg and Basel-Stadt. In addition to these changes, a number of other adaptations have been made to the Healthcare Benefits Ordinance and its annexes.

Author: Andreas Wildi
Read more

Recent updates

Katie Lee Federal Court of Appeal remands Remicade new use patent decision on anticipation and obviousness

Canada - Smart & Biggar

Authors: Katie Lee, Urszula Wojtyra
Andreas Wildi Swiss health study commenced

Switzerland - Walder Wyss

Author: Andreas Wildi
Riccardo Fruscalzo AIFA guidance on management of clinical trials during COVID-19 emergency

Italy - Hogan Lovells

Authors: Riccardo Fruscalzo, Carlotta Busani
Catherine Drew COVID-19 crisis: clinical trials and cross-border collaboration

United Kingdom - Pinsent Masons

Author: Catherine Drew
Anne-Sophie Raxhon DPA approves draft act prohibiting life and health insurers from processing health tracker data

Belgium - ALTIUS

Authors: Anne-Sophie Raxhon, Jan Clinck
Rainer Herzig Leucopenia medicine and reimbursement code

Austria - Preslmayr Attorneys at Law

Author: Rainer Herzig